SLU-PP-332
A small-molecule ERRα agonist studied as an 'exercise in a pill' candidate that activates pathways triggered by physical training.
Overview
SLU-PP-332 is a small-molecule activator of estrogen-related receptor alpha (ERRα), discovered at Saint Louis University. Animal studies showed it increased endurance, raised metabolic rate, and improved fat oxidation, mimicking adaptations normally induced by exercise. Human trials are not yet available, but it has become a focal point of longevity and exercise-mimetic research.
Benefits
- May increase endurance and exercise capacity
- Supports fat oxidation
- Activates exercise-adaptation pathways without training
- Improves metabolic rate in animal models
Mechanism of Action
Activates ERRα, a transcription factor that drives mitochondrial biogenesis, oxidative metabolism, and the gene-expression changes typically induced by endurance exercise.
Dosage (informational only)
- Typical range
- Research-only; human dosing not established
- Frequency
- Animal studies use daily dosing
Technically a small molecule rather than a peptide, but commonly grouped with metabolic peptides in research discussions.
Side Effects
- No human safety data available
- Theoretical concerns about chronic ERRα activation
Related peptides
A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise capacity.
A synthetic tetrapeptide developed in Russia, studied extensively for telomerase activation and aging biomarkers.
A designer peptide that selectively triggers apoptosis in senescent cells, an emerging anti-aging strategy.